Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

ARA-290 vs Glow

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

ARA-290 has stronger documented evidence (Phase 2) than Glow (Anecdotal) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, ARA-290 is the safer pick. Glow may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

ARA-290

Phase 2

Glow

Anecdotal

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

ARA-290 Glow
Class EPO-derived peptide; innate repair receptor (IRR) agonist Three-component regenerative blend (matrikine + cytoprotective + actin-regulator)
Drug class Tissue Repair Tissue Repair
Mechanism Activates IRR heterocomplex (EpoR/βcR); tissue protection without hematopoietic effect Layered remodelling: GHK-Cu's copper-peptide matrikine signal upregulates collagen and elastin transcription and engages roughly 4,000 wound-healing genes; BPC-157 drives angiogenesis via VEGFR2 and stabilises epithelial / connective-tissue repair; TB-500 sequesters G-actin to enable cell migration and amplifies stem-cell mobilisation. Together: matrix synthesis + vessel-bed repair + cell-migration substrate.
Route SC injection SC injection
Half-life ~2 hrs Composite: hours (BPC-157 / GHK-Cu) to days (TB-500 tissue uptake)
Dosage (research) 2-4 mg SC daily for 28 days (trial protocol) Typical SC protocols deliver ~250-500 mcg per component daily for 4-6 week loading cycles. Confirm per-component dose from the vial total before reconstitution
Evidence tier Phase 2 Anecdotal
Research depth 68 indexed (PubMed 51 · CT 4 · EPMC 13) —
Availability Investigational Compounding Restricted
Reported risks Injection site reactions; Phase 2/3 data limited No human trials of the combined formulation; TB-500 WADA-banned with theoretical pro-proliferative concerns; chronic GHK-Cu raises copper-accumulation considerations at high doses; injection-site reactions

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick ARA-290 or Glow?

ARA-290 has stronger documented evidence (Phase 2) than Glow (Anecdotal) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, ARA-290 is the safer pick. Glow may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between ARA-290 and Glow?

ARA-290 is classed as EPO-derived peptide; innate repair receptor (IRR) agonist; Glow is classed as Three-component regenerative blend (matrikine + cytoprotective + actin-regulator). Reported mechanism: ARA-290, Activates IRR heterocomplex (EpoR/βcR); tissue protection without hematopoietic effect; Glow, Layered remodelling: GHK-Cu's copper-peptide matrikine signal upregulates collagen and elastin transcription and engages roughly 4,000 wound-healing genes; BPC-157 drives angiogenesis via VEGFR2 and stabilises epithelial / connective-tissue repair; TB-500 sequesters G-actin to enable cell migration and amplifies stem-cell mobilisation. Together: matrix synthesis + vessel-bed repair + cell-migration substrate. Reported half-life: ARA-290, ~2 hrs; Glow, Composite: hours (BPC-157 / GHK-Cu) to days (TB-500 tissue uptake). Routes in published studies: ARA-290, SC injection; Glow, SC injection.

Which has stronger evidence, ARA-290 or Glow?

ARA-290 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. ARA-290 is graded Phase 2, with 3 cited sources on its reference page and 68 indexed studies. Glow is graded Anecdotal, with 3 cited sources on its reference page.

Which is more accessible, ARA-290 or Glow?

Neither ARA-290 nor Glow is an FDA-approved drug. Catalog status: ARA-290, Investigational; Glow, Compounding Restricted.

Are ARA-290 and Glow ever combined?

ARA-290 and Glow appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…